PDF herunterladen
Clin Colon Rectal Surg 2024; 37(02): 090-095
DOI: 10.1055/s-0042-1758759
Review Article

Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastases

Rupen Shah
1   Division of Surgical Oncology, Henry Ford Cancer Institute/Henry Ford Health, Detroit, Michigan
,
Alexandra Gangi
2   Division of Surgical Oncology, Cedars Sinai Medical Center, Los Angeles, California
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Peritoneal metastases from colon cancer are a particularly challenging disease process given the limited response to systemic chemotherapy. In patients with isolated peritoneal metastases, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy offers a potential treatment option to these patients with limited peritoneal metastases as long as a complete cytoreduction is achieved. Decision about a patient's candidacy for this treatment modality should be undertaken by a multidisciplinary group at expert centers.

Keywords

peritoneal carcinomatosis - cytoreductive surgery - HIPEC


Publikationsverlauf

Artikel online veröffentlicht:
13. März 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72 (01) 7-33
    Google Scholar
  • 2 van den Berg I, Coebergh van den Braak RRJ, van Vugt JLA, Ijzermans JNM, Buettner S. Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study. World J Surg Oncol 2021; 19 (01) 96
    CrossrefPubMedGoogle Scholar
  • 3 Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. BioMed Res Int 2014; 2014: 782890 DOI: 10.1155/2014/782890.
    CrossrefPubMedGoogle Scholar
  • 4 Massalou D, Benizri E, Chevallier A. et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg 2017; 213 (02) 377-387
    CrossrefPubMedGoogle Scholar
  • 5 Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. Recent Results Cancer Res 2007; 169: 11-23
    PubMedGoogle Scholar
  • 6 Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012; 7 (10) e47054
    CrossrefPubMedGoogle Scholar
  • 7 Schneider MA, Eden J, Pache B. et al. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg 2018; 268 (05) 845-853
    CrossrefPubMedGoogle Scholar
  • 8 van Santvoort HC, Braam HJ, Spekreijse KR. et al. Peritoneal carcinomatosis in t4 colorectal cancer: occurrence and risk factors. Ann Surg Oncol 2014; 21 (05) 1686-1691
    CrossrefPubMedGoogle Scholar
  • 9 van Gestel YR, Thomassen I, Lemmens VE. et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 2014; 40 (08) 963-969
    CrossrefPubMedGoogle Scholar
  • 10 Sugarbaker PH. Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer. World J Surg 1995; 19 (02) 235-240
    CrossrefPubMedGoogle Scholar
  • 11 Nindra U, Shahnam A, Mahon KL. Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis. Asia Pac J Clin Oncol 2022; 18 (01) 7-12
    CrossrefPubMedGoogle Scholar
  • 12 Hill M, Norman A, Cunningham D. et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995; 13 (09) 2317-2323
    CrossrefPubMedGoogle Scholar
  • 13 Bauman MD, Becerra DG, Kilbane EM. et al. Laparoscopic distal pancreatectomy for pancreatic cancer is safe and effective. Surg Endosc 2018; 32 (01) 53-61
    CrossrefPubMedGoogle Scholar
  • 14 Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 1999; 79 (11-12): 1800-1805
    CrossrefPubMedGoogle Scholar
  • 15 Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 2011; 22 (10) 2250-2256
    CrossrefPubMedGoogle Scholar
  • 16 Kerscher AG, Chua TC, Gasser M. et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 2013; 108 (07) 1432-1439
    CrossrefPubMedGoogle Scholar
  • 17 Waite K, Youssef H. The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review. Ann Surg Oncol 2017; 24 (03) 705-720
    CrossrefPubMedGoogle Scholar
  • 18 Gilly FN. International Registry of Colorectal Carcinomatosis. Phase II studies: International registry of colorectal carcinomatosis. Eur J Surg Oncol 2006; 32 (06) 648-654
    CrossrefPubMedGoogle Scholar
  • 19 Glehen O, Kwiatkowski F, Sugarbaker PH. et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22 (16) 3284-3292
    CrossrefPubMedGoogle Scholar
  • 20 Ceelen W, Van Nieuwenhove Y, Putte DV, Pattyn P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol 2014; 21 (09) 3023-3028
    CrossrefPubMedGoogle Scholar
  • 21 Passot G, Vaudoyer D, Cotte E. et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg 2012; 256 (01) 125-129
    CrossrefPubMedGoogle Scholar
  • 22 Chua TC, Morris DL, Saxena A. et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol 2011; 18 (06) 1560-1567
    CrossrefPubMedGoogle Scholar
  • 23 Cashin PH, Mahteme H, Spång N. et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 2016; 53: 155-162
    CrossrefPubMedGoogle Scholar
  • 24 van Oudheusden TR, Braam HJ, Luyer MD. et al. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis. Ann Surg Oncol 2015; 22 (04) 1236-1242
    CrossrefPubMedGoogle Scholar
  • 25 Dresen RC, De Vuysere S, De Keyzer F. et al. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases. Cancer Imaging 2019; 19 (01) 1
    CrossrefPubMedGoogle Scholar
  • 26 van 't Sant I, Engbersen MP, Bhairosing PA. et al. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur Radiol 2020; 30 (06) 3101-3112
    CrossrefPubMedGoogle Scholar
  • 27 van 't Sant I, van Eden WJ, Engbersen MP. et al. Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. Br J Surg 2019; 106 (04) 491-498
    CrossrefPubMedGoogle Scholar
  • 28 Cotte E, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O. Management of peritoneal carcinomatosis from colorectal cancer: current state of practice. Cancer J 2009; 15 (03) 243-248
    CrossrefPubMedGoogle Scholar
  • 29 Esquivel J, Chua TC, Stojadinovic A. et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol 2010; 102 (06) 565-570
    CrossrefPubMedGoogle Scholar
  • 30 Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 2013; 100 (02) 285-292
    CrossrefPubMedGoogle Scholar
  • 31 Marmor RA, Kelly KJ, Lowy AM, Baumgartner JM. Laparoscopy is safe and accurate to evaluate peritoneal surface metastasis prior to cytoreductive surgery. Ann Surg Oncol 2016; 23 (05) 1461-1467
    CrossrefPubMedGoogle Scholar
  • 32 Hentzen JEKR, van der Plas WY, Constansia RDN. et al. Role of diagnostic laparoscopy in patients with suspicion of colorectal peritoneal metastases to evaluate suitability for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. BJS Open 2019; 3 (06) 812-821
    CrossrefPubMedGoogle Scholar
  • 33 Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43 (suppl): S15-S25
    CrossrefPubMedGoogle Scholar
  • 34 Elias D, Gilly F, Boutitie F. et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28 (01) 63-68
    CrossrefPubMedGoogle Scholar
  • 35 Goéré D, Souadka A, Faron M. et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 2015; 22 (09) 2958-2964
    CrossrefPubMedGoogle Scholar
  • 36 Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-374
    CrossrefPubMedGoogle Scholar
  • 37 Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open 2019; 3 (05) 585-594
    CrossrefPubMedGoogle Scholar
  • 38 Narasimhan V, Tan S, Kong J. et al. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis. Colorectal Dis 2020; 22 (11) 1482-1495
    CrossrefPubMedGoogle Scholar
  • 39 Elias D, Blot F, El Otmany A. et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92 (01) 71-76
    CrossrefPubMedGoogle Scholar
  • 40 Shen P, Levine EA, Hall J. et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138 (01) 26-33
    CrossrefPubMedGoogle Scholar
  • 41 Gervais MK, Dubé P, McConnell Y, Drolet P, Mitchell A, Sideris L. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer. J Surg Oncol 2013; 108 (07) 438-443
    CrossrefPubMedGoogle Scholar
  • 42 Verwaal VJ, van Ruth S, de Bree E. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21 (20) 3737-3743
    CrossrefPubMedGoogle Scholar
  • 43 Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15 (09) 2426-2432
    CrossrefPubMedGoogle Scholar
  • 44 Mirnezami R, Mehta AM, Chandrakumaran K. et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer 2014; 111 (08) 1500-1508
    CrossrefPubMedGoogle Scholar
  • 45 Quénet F, Elias D, Roca L. et al; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (02) 256-266
    CrossrefPubMedGoogle Scholar
  • 46 Klaver CEL, Wisselink DD, Punt CJA. et al; COLOPEC collaborators group. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 2019; 4 (10) 761-770
    CrossrefPubMedGoogle Scholar
  • 47 Goéré D, Glehen O, Quenet F. et al; BIG-RENAPE group. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol 2020; 21 (09) 1147-1154
    CrossrefPubMedGoogle Scholar
  • 48 Arjona-Sánchez A, Barrios P, Boldo-Roda E. et al. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of hyperthermic intra-peritoneal chemotherapy (HIPEC) with mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer 2018; 18 (01) 183 DOI: 10.1186/s12885-018-4096-0.
    CrossrefPubMedGoogle Scholar
  • 49 Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228 (03) 347-354
    CrossrefPubMedGoogle Scholar
  • 50 Jacquet P, Stephens AD, Averbach AM. et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996; 77 (12) 2622-2629
    CrossrefPubMedGoogle Scholar
  • 51 Foster JM, Sleightholm R, Patel A. et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open 2019; 2 (01) e186847
    CrossrefPubMedGoogle Scholar
  • 52 McQuellon RP, Danhauer SC, Russell GB. et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2007; 14 (03) 1105-1113
    CrossrefPubMedGoogle Scholar
  • 53 McQuellon RP, Loggie BW, Lehman AB. et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10 (02) 155-162
    CrossrefPubMedGoogle Scholar
  • 54 Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005; 31 (01) 53-58
    CrossrefPubMedGoogle Scholar
  • 55 Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2006; 13 (12) 1627-1632
    CrossrefPubMedGoogle Scholar
  • 56 Hill AR, McQuellon RP, Russell GB, Shen P, Stewart IV JH, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol 2011; 18 (13) 3673-3679
    CrossrefPubMedGoogle Scholar
  • 57 Leimkühler M, Hentzen JEKR, Hemmer PHJ. et al. Systematic review of factors affecting quality of life after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2020; 27 (10) 3973-3983
    CrossrefPubMedGoogle Scholar